Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.
Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.
复制标题
DOI：
10.7759/cureus.14099
复制
发表时间：
2021-03-25
期刊：
影响因子：
--
通讯作者：
Atluri P
中科院分区：
文献类型：
--
作者：
Malayala SV;Mohan G;Vasireddy D;Atluri P
从2020年12月开始，俗称“现代疫苗”的mRNA-1273疫苗在美国广泛接种，用于预防COVID-19感染。在与疫苗相关的试验中，报告了轻度至中度的副作用，如低烧、肌痛、发冷和不适。在此病例报告中，我们报告了一例紫癜皮疹和血小板减少后接受第一剂m-RNA-1273疫苗。本例患者是一名60岁男性患者，他接种了第一剂疫苗，在两天内出现弥漫性丘疹，伴有一些血小板减少症。他有吸烟史，丙型肝炎肝硬化，慢性肾病4期，未经治疗的高血压和收缩期充血性心力衰竭。通过对有限的与该疫苗及其副作用相关的文献的回顾，并没有其他病因可以解释皮疹的突然发作，我们将这种血小板减少症和紫癜性皮疹归因于mRNA-1273疫苗的副作用。
The mRNA-1273 vaccine, popularly called the "Moderna vaccine" is being widely administered in the United States for the prevention of COVID-19 infection since December 2020. Mild to moderate intensity side effects like low-grade fever, myalgia, chills and malaise were reported in the trials related to the vaccine. With this case report, we report a case of purpuric rash and thrombocytopenia after receiving the first dose of the m-RNA-1273 vaccine. The patient, in this case, is a 60-year-old male patient who received the first vaccine dose and within two days, he developed diffuse papular rash associated with some thrombocytopenia. He had a history of tobacco use, Hepatitis C liver cirrhosis, chronic kidney disease stage 4, untreated hypertension and systolic congestive heart failure at the baseline. With review of the limited literature related to the vaccine and its side effect profile and with no other etiology explaining the sudden onset of rash, we attribute this thrombocytopenia and purpuric rash as the side effects of the mRNA-1273 vaccine.